Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations

There are major hurdles to the use of tyrosine kinase inhibitors (TKIs) and any other agents with significant toxicities (which means practically the preponderance of potential effective agents) in the context of prevention/anti-progression (interception) studies. We will discuss epidermal growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragnev, Konstantin H., Dragnev, Christo P. C., Lubet, Ronald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165497/
https://www.ncbi.nlm.nih.gov/pubmed/37169023
http://dx.doi.org/10.3389/fcell.2023.1170444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165497/
https://www.ncbi.nlm.nih.gov/pubmed/37169023
http://dx.doi.org/10.3389/fcell.2023.1170444

Ejemplares similares